* For illustration purpose only
Active Ingredient: Cefixime
Utilization: Used to treat infections of respiratory and urinary systems
Available Dosages: 100mg and 200mg
Last purchase: 34 minutes ago
There are 20 users looking at this product right now
Suprax (Cefixime) - refers to the semi-synthetic antibiotics of the cephalosporin series. It has a pronounced bactericidal effect. It has a destructive effect on many gram-negative, gram-positive microorganisms.
Used to treat infections of respiratory and urinary systems
Indication for use
Suprax (Cefixime) can be taken by almost all adults and children over 12 who have:
· acute bronchitis and chronic bronchitis;
· acute otitis media;
· streptococcal tonsillitis and pharyngitis;
· uncomplicated gonorrhea;
· uncomplicated urinary tract infections;
Suprax (Cefixime) is not recommended to use if you have: hypersensitivity to the active substance or any other of the medication components; porphyria.
In case of pregnancy or breast-feeding you have to consult with your doctor.
Dose and usage
Dose of Suprax (Cefixime): 200 mg yellow and white capsules, containing a mixture of powder and small granules of yellowish-white color; 400 mg purple and white capsules containing a mixture of powder and small granules of yellowish-white color.
Granules for suspension (60 ml in tanned bottle) : small granules from white to cream color.
Before taking this medication consult with your attending physician.
For adults and children over 12 years old with a body weight of more than 50 kg, the daily dose is 400 mg (1 time / day or 200 mg 2 times / day). The duration of treatment is 7-10 days. With uncomplicated gonorrhea - 400 mg once.
As any others medications Suprax (Cefixime) can have in some cases side effects such as: nausea, vomiting, diarrhea, heartburn; indigestion, abdominal pain; headache, dizziness; urticaria, skin rashes, itching; fever, facial swelling.
Tell your doctor if you have some side effects or your condition worsens.
Medically reviewed by Dr. Josette Davignon
Last updated: 27.01.2022